Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
You may also be interested in...
Pfizer’s results may have heralded a third-quarter stabilization of pandemic-related effects had the costs and expectations for its vaccine not hijacked sentiment.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
Roche’s ipatasertib has improved progression-free survival in a sub-group of previously untreated metastatic castration-resistant prostate cancer patients – those whose tumors had PTEN loss – in a Phase III study. However the AKT inhibitor failed to cut the risk of disease worsening or death in the broader population.